Top-News

Alkermes Aktie News

Aktie
WKN:  A1JKVH ISIN:  IE00B56GVS15 US-Symbol:  ALKS
29,52 $
+0,22 $
+0,75%
25,353 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
4,06 Mrd. €
Streubesitz
100,00%
KGV
-
Index-Zuordnung
-

Alkermes News

17.04.25 - PR Newswire
Alkermes to Report First Quarter Financial Results on May 1, 2025
Alkermes to Report First Quarter Financial Results on May 1, 2025 PR Newswire
17.04.25 - PR Newswire
Alkermes to Report First Quarter Financial Results on May 1, 2025
Alkermes to Report First Quarter Financial Results on May 1, 2025 PR Newswire
02.04.25 - PR Newswire
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference PR Newswire
02.04.25 - PR Newswire
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference PR Newswire
01.04.25 - PR Newswire
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia PR Newswire
01.04.25 - PR Newswire
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia PR Newswire
27.03.25 - PR Newswire
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder PR ...
27.03.25 - PR Newswire
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder PR ...
11.03.25 - LYNX Analysen
Alkermes: Diese Aktie scheint durchstarten zu wollen
Das irische Pharmaunternehmen hat sich auf die Entwicklung von Medikamenten für schwer zu behandelnde psychiatrische und neurologische Erkrankungen spezialisiert. Die ...
26.02.25 - PR Newswire
Alkermes to Participate in Upcoming Investor Conferences
Alkermes to Participate in Upcoming Investor Conferences PR Newswire
26.02.25 - PR Newswire
Alkermes to Participate in Upcoming Investor Conferences
Alkermes to Participate in Upcoming Investor Conferences PR Newswire
12.02.25 - PR Newswire
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 PR Newswire
12.02.25 - PR Newswire
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 PR Newswire
05.02.25 - PR Newswire
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 PR Newswire
05.02.25 - PR Newswire
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 PR Newswire
02.01.25 - PR Newswire
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
02.01.25 - PR Newswire
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »